Canada - inglese - Health Canada

pharmascience inc - amantadine hydrochloride - syrup - 50mg - amantadine hydrochloride 50mg - adamantanes

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride capsules, usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride capsules, usp are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. amantadine hydrochloride capsules, usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. amantadine hydrochloride capsules, usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness. there are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules, usp will avoid the development of influenza a virus pneumonitis or other complications in high risk patients. there is no clinical evidence indicating that amantadine hydrochloride capsules, usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains. the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules, usp. - amantadine hydrochloride capsules, usp are not a substitute for early vaccination on   an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance mutations could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules, usp. amantadine hydrochloride capsules, usp are indicated in the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. in the treatment of parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-l-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. amantadine hydrochloride capsules, usp are contraindicated in patients with known hypersensitivity to amantadine hydrochloride or to any of the other ingredients in amantadine hydrochloride capsules, usp.

Stati Uniti - inglese - NLM (National Library of Medicine)

american health packaging - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. influenza a prophylaxis amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. influenza a treatment amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory trac

Stati Uniti - inglese - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride tablets  are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride tablets  are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. influenza a prophylaxis amantadine hydrochloride tablets  are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. influenza a treatment amantadine hydrochloride tablets  are also indicated in the treatment

Stati Uniti - inglese - NLM (National Library of Medicine)

alembic pharmaceuticals limited - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride tablets  are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride tablets  are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. influenza a prophylaxis amantadine hydrochloride tablets  are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. influenza a treatment amantadine hydrochloride tablets  are also indicated in the treatment

Stati Uniti - inglese - NLM (National Library of Medicine)

atlantic biologicals corp. - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride oral solution usp is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine hydrochloride does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine hydrochloride prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness. there are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride will avoid the development of influenza a virus pneumonitis or other complications in high risk patients. there is no clinical evidence indicating that amantadine hydrochloride is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains. the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride: - amantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance mutations could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride. amantadine hydrochloride is indicated in the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. in the treatment of parkinson's disease, amantadine hydrochloride is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-l-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. although anticholinergic-type side effects have been noted with amantadine hydrochloride when used in patients with drug-induced extrapyramidal reactions, there is lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. amantadine hydrochloride oral solution usp is contraindicated in patients with known hypersensitivity to amantadine hydrochloride or any of the other ingredients in the drug.

Stati Uniti - inglese - NLM (National Library of Medicine)

remedyrepack inc. - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness. there are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza a virus pneumonitis or other complications in high-risk patients. there is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains. the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: - amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance mutations could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride tablets. amantadine hydrochloride tablets are indicated in the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. in the treatment of parkinson's disease, amantadine hydrochloride tablets are less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-l-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. amantadine hydrochloride tablets are indicated in the treatment of drug-induced extrapyramidal reactions. although anticholinergic-type side effects have been noted with amantadine hydrochloride tablets when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. amantadine hydrochloride tablets are contraindicated in patients with known hypersensitivity to amantadine hydrochloride or to any of the other ingredients in amantadine hydrochloride tablets.

Stati Uniti - inglese - NLM (National Library of Medicine)

epic pharma llc - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride capsules, usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride capsules, usp are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. amantadine hydrochloride capsules, usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. amantadine hydrochloride capsules, usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness. there are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules, usp will avoid the development of influenza a virus pneumonitis or other complications in high risk patients. there is no clinical evidence indicating that amantadine hydrochloride capsules, usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains. the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules, usp. amantadine hydrochloride capsules, usp are indicated in the treatment of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. in the treatment of parkinson’s disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-l-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. amantadine hydrochloride, usp is indicated in the treatment of drug-induced extrapyramidal reactions. although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. amantadine hydrochloride capsules, usp are contraindicated in patients with known hypersensitivity to amantadine hydrochloride or to any of the other ingredients in amantadine hydrochloride capsules, usp.

Canada - inglese - Health Canada

mylan pharmaceuticals ulc - amantadine hydrochloride - capsule - 100mg - amantadine hydrochloride 100mg - adamantanes

Canada - inglese - Health Canada

pharmel inc - amantadine hydrochloride - capsule - 100mg - amantadine hydrochloride 100mg - adamantanes